Robert L McFarland

Robert L. McFarland serves as a key procurement lead within the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), supporting the agency’s mission to accelerate the translation of scientific discoveries into clinical applications. He manages a portfolio of acquisitions focused on advanced laboratory technologies, high-throughput screening systems, and automated analytical platforms essential to translational research. His work directly enables the development and validation of tissue chip systems, precision metabolite synthesis tools, and other innovative biomedical technologies, ensuring that NCATS maintains cutting-edge research infrastructure through timely and compliant contracting practices. McFarland collaborates with a diverse array of contractors, including specialized testing laboratories, research and development firms, and biotechnology service providers. His procurement patterns reflect a preference for technical partners with proven expertise in life sciences R&D, laboratory automation, and analytical instrumentation. While no single contractor dominates his portfolio, he consistently engages vendors capable of delivering scalable, reproducible solutions aligned with NIH standards for data integrity and experimental reproducibility. His contracting approach demonstrates a strong commitment to small business participation, with nearly 29% of awards designated as total small business set-asides under FAR 19.5. While the majority of acquisitions remain open to all competitors, his consistent use of small business set-asides signals a deliberate strategy to foster innovation from emerging firms and expand the pool of qualified vendors in the translational research ecosystem. McFarland’s procurement focus centers on NAICS codes 541380 (Testing Laboratories and Services) and 541715 (R&D in Physical, Engineering, and Life Sciences), reflecting deep engagement with contract research organizations, analytical service providers, and specialized R&D firms. He routinely procures high-performance instrumentation, automated assay platforms, and proprietary reagent systems critical to early-stage therapeutic development, demonstrating expertise in life sciences procurement within a federally funded research environment.